{"success":true,"data":{"pressRelease":{"id":"154837","rtpr_id":"nNFC8Ky5R6-20260929","ticker":"TELO","exchange":"","all_tickers":["TELO"],"title":"Telo Genomics Reports Additional Clinical Research Results Comparing Blood-Based TELO-MRD with Bone-Marrow Next-Generation Flow and Next-Generation Sequencing","author":"Newsfile Corp","published_at":"2026-09-29T07:30:16.072Z","article_body":"In matched Cleveland Clinic and Jewish General Hospital samples, blood-based\nTELO enumeration detected circulating plasma cells in all Adaptive\nclonoSEQ-positive cases reviewed and in a series of clonoSEQ-negative or\nnon-evaluable samples; previously reported EuroFlow comparison data are also\nsummarized.\n\nVancouver, British Columbia--(Newsfile Corp. - September 29, 2026) - Telo\nGenomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the \"Company\" or \"Telo Genomics\"),\na leader in the development of diagnostic and prognostic tests based on\nthree-dimensional analysis of telomeres (which are the ends of chromosomes),\ntoday reported additional clinical research results from its TELO-MRD program\nfor multiple myeloma, including a comparison of blood-based TELO enumeration\nwith matched bone marrow Adaptive clonoSEQ next-generation sequencing (\"NGS\")\nMRD testing.\n\nTELO-MRD is a type of liquid-biopsy applied to finding Minimal Residual\nDisease (MRD) in samples of peripheral blood. It combines enumeration of\ncirculating tumor cells (\"CTCs\"), specifically malignant plasma cells, with\nthree-dimensional telomere profiling of those cells using the Company's\nproprietary TeloView® platform. The assay is designed to detect minimal\nresidual disease in peripheral blood but also within malignant cells can\nassess the hallmarks of genomic instability. That combination is intended to\nhelp distinguish patients whose residual cells appear biologically at lesser\nrisk from patients whose residual disease demonstrate features associated with\na higher risk of relapse or lack of response to therapy.\n\nThe analytic sensitivity of other MRD tests for multiple myeloma are reliant\non the collection of bone marrow, a significantly invasive procedure, using\nnext-generation flow cytometry (including EuroFlow next-generation flow, or\n\"NGF\") or next-generation sequencing such as Adaptive Biotechnologies'\nclonoSEQ® assay. Those methods quantify residual tumor burden. Because of the\nrequirement for bone marrow aspirates for a disease that is typically patchy\nin its distribution, there is a risk of false negative results. In the case of\nclonotype-dependent NGS, there is the added requirement that a dominant clone\ncan first be identified. Importantly, both of these tests provide limited\ninformation about the biological aggressiveness of any cells that remain.\n\nThe Company previously reported a head-to-head analysis of blood-based\nTELO-MRD against matched bone-marrow EuroFlow NGF. Among 42 evaluable samples\nwith exact patient- and date-matched EuroFlow NGF results, TELO-MRD detected\ncirculating myeloma cells in 39/42 samples (92.9%), compared with MRD\ndetection in 23/42 samples (54.8%) by EuroFlow NGF. That comparison was based\non a limited, matched cohort and requires confirmation in larger, independent\nstudies.\n\nThe Company is now reporting a separate comparison of blood-based manual TELO\nenumeration with matched bone-marrow Adaptive clonoSEQ MRD results from two\nindependent research cohorts at Cleveland Clinic and Jewish General Hospital.\nA total of 17 matched comparisons were available, including baseline clonality\nassessments and longitudinal MRD follow-up samples. Manual TELO blood\nenumeration identified circulating plasma cells in every evaluable specimen,\nincluding all cases that were Adaptive-positive or Positive Below Limit of\nDetection.\n\nAmong 10 matched longitudinal MRD assessments, all Adaptive-positive samples\nand all Positive-Below-LOD samples (5 of 10) were also positive by TELO. In\naddition, all 4 samples classified as MRD-negative by Adaptive retained\ndetectable circulating plasma cells by TELO enumeration, and the 1 sample that\nwas not evaluable by Adaptive was TELO-positive. No case was identified in\nwhich Adaptive detected residual disease while TELO blood enumeration was\nnegative. These blood and bone-marrow results are complementary comparisons of\ndifferent sample types and methods, not a claim that the assays are\ninterchangeable.\n\nTwo patients were not trackable by Adaptive because a dominant clonotype could\nnot be established. TELO identified circulating plasma cells in these\npatients, indicating that cell-based analysis remained informative when\nclonotype-dependent molecular MRD could not be performed. The Adaptive\ncomparison is based on a limited research dataset, includes manual\nenumeration, and requires confirmation in larger, independent studies with\nstandardized assay procedures.\n\n\"These additional research results are consistent with what we have seen\nversus bone-marrow flow cytometry,\" said John Farlinger, Chief Executive\nOfficer and Chairman of Telo Genomics. \"In this Adaptive clonoSEQ comparison,\nblood-based TELO enumeration was positive in every Adaptive-positive sample\nreviewed and also detected circulating plasma cells in Adaptive-negative and\nnon-evaluable samples. We believe a blood-based, cell-based method can\ncomplement marrow NGS and NGF, particularly when a clone cannot be tracked or\nresidual cells may be missed in a single marrow site.\"\n\n\"Direct identification of circulating myeloma cells does not depend on first\nlocking a dominant clonotype,\" said Dr. Sabine Mai, Co-Founder and Director of\nTelo Genomics. \"That is a practical difference versus clonotype-dependent NGS.\nThese data are preliminary, the sample size is small, and blood is not the\nsame compartment as bone marrow. The next step is to confirm both detection\nand the biological profiling of those cells in larger studies.\"\n\n\"Accurate, reliable and efficient peripheral blood MRD testing is a priority\nfor our patients with myeloma who are currently undergoing recurrent bone\nmarrow biopsies for this important disease response assessment. Telo not only\nachieves this need, but with the single cell telomere technology can go well\nbeyond MRD assessment to help us better understand the behavior of plasma\ncells. I am quite excited about future research results as we continue to work\nwith Telo,\" said Dr. Sandra Mazzoni, of the Cleveland Clinic.\n\nThe study was a limited, matched research comparison. TELO counts in this\ndataset were generated by manual enumeration. Differences between a blood\nassay and a bone-marrow NGS assay may reflect residual cells in circulation,\nspatial heterogeneity of myeloma, differences in analytical targets, or\nfalse-positive or false-negative calls by either method. These results should\nnot be interpreted as a head-to-head clinical performance claim or as a basis\nfor treatment decisions.\n\nWhile TELO-MRD is not yet commercially available, the Company intends to\ncontinue development of TELO-MRD, including analytical validation of automated\nworkflows, with the objective of a commercial application by the end of\ncalendar 2027.\n\nMultiple myeloma remains incurable. Therapy has extended survival, but\nresidual cancer cells persist and most patients eventually relapse. The\nCompany believes that combining sensitive blood-based detection of residual\nmyeloma cells with single-cell 3D telomere profiling could, if further\nvalidated, add information beyond tumor-burden measurements from bone-marrow\nNGF or NGS alone.\n\nAbout Telo Genomics\n\nTelo Genomics is a biotech company pioneering the most comprehensive telomere\nplatform in the industry with powerful applications and prognostic solutions.\nThese include liquid biopsies and related technologies in oncology and\nneurological diseases. Liquid biopsy is a rapidly growing field of significant\ninterest to the medical community for being less invasive and more easily\nreplicated than traditional diagnostic approaches. By combining our team's\nconsiderable expertise in quantitative analysis of 3D telomeres with molecular\nbiology and artificial intelligence to recognize disease associated genetic\ninstability, Telo Genomics is developing simple and accurate products that\nimprove day-to-day care for patients by serving the needs of pathologists,\nclinicians, academic researchers and drug developers. The benefits of our\nproprietary technology have been substantiated in 190+ peer reviewed\npublications and in 30+ clinical studies involving more than 3,000 patients\nwith multiple cancers and Alzheimer's disease. Our lead application, Telo-MM,\nis being developed to provide important, actionable information to medical\nprofessionals in the treatment of multiple myeloma, a deadly form of blood\ncancer. For more information, please visit www.telodx.com.\n\nFor further information, please contact:\n\nJohn Price, Chief Financial Officer\nJohn.Price@telodx.com\nTel: 408-550-5767\n555 Richmond Street West\nToronto, ON, Canada, M5V 3B1\nwww.telodx.com\n\nNeither the TSX Venture Exchange nor its Regulation Services Provider (as such\nterm is defined in the policies of the TSX Venture Exchange) accepts\nresponsibility for the adequacy or accuracy of this release.\n\nCautionary Note Regarding Forward-Looking Statements\n\nCertain information in this news release may constitute \"forward-looking\ninformation\" under Canadian securities legislation. Forward-looking\ninformation is often identified by words such as \"intends,\" \"believes,\" \"may,\"\n\"could,\" \"objective,\" \"estimate,\" or statements that certain events \"will\"\noccur. Forward-looking statements in this release include, without limitation,\nstatements regarding further development and potential commercialization of\nTELO-MRD by the end of calendar 2027; the complementary role of TELO-MRD\nrelative to bone-marrow NGF and NGS assays; potential future applications of\nthe platform; and the Company's plans to continue research, analytical\nvalidation and development. Forward-looking statements are based on\nassumptions that the Company considers reasonable as of the date of this\nrelease, including that additional studies will confirm the results described\nherein, that development and regulatory or laboratory-developed-test pathways\nwill proceed as planned, and that funding and collaboration partners will\nremain available. Those assumptions may prove incorrect. Actual results may\ndiffer materially because of known and unknown risks and uncertainties,\nincluding the risk that additional clinical data will not confirm these\nfindings, that comparisons of blood-based and bone-marrow assays will be\ninterpreted differently by clinicians or regulators, that apparent\nTELO-positive / NGS-negative results will not be reproduced or will not prove\nclinically meaningful, that commercialization may be delayed or may not occur,\nand other risks described in the Company's filings on SEDAR+. Readers should\nnot place undue reliance on forward-looking statements. The Company does not\nundertake to update forward-looking statements except as required by\napplicable securities laws.\n\n\nTo view the source version of this press release, please visit\nhttps://www.newsfilecorp.com/release/316474","article_body_html":"","raw_payload":{"data":{"id":"nNFC8Ky5R6-20260929","title":"Telo Genomics Reports Additional Clinical Research Results Comparing Blood-Based TELO-MRD with Bone-Marrow Next-Generation Flow and Next-Generation Sequencing","author":"Newsfile Corp","ticker":"TELO","created":"2026-09-29T07:30:16.072Z","tickers":["TELO"],"exchange":"","article_body":"In matched Cleveland Clinic and Jewish General Hospital samples, blood-based\nTELO enumeration detected circulating plasma cells in all Adaptive\nclonoSEQ-positive cases reviewed and in a series of clonoSEQ-negative or\nnon-evaluable samples; previously reported EuroFlow comparison data are also\nsummarized.\n\nVancouver, British Columbia--(Newsfile Corp. - September 29, 2026) - Telo\nGenomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the \"Company\" or \"Telo Genomics\"),\na leader in the development of diagnostic and prognostic tests based on\nthree-dimensional analysis of telomeres (which are the ends of chromosomes),\ntoday reported additional clinical research results from its TELO-MRD program\nfor multiple myeloma, including a comparison of blood-based TELO enumeration\nwith matched bone marrow Adaptive clonoSEQ next-generation sequencing (\"NGS\")\nMRD testing.\n\nTELO-MRD is a type of liquid-biopsy applied to finding Minimal Residual\nDisease (MRD) in samples of peripheral blood. It combines enumeration of\ncirculating tumor cells (\"CTCs\"), specifically malignant plasma cells, with\nthree-dimensional telomere profiling of those cells using the Company's\nproprietary TeloView® platform. The assay is designed to detect minimal\nresidual disease in peripheral blood but also within malignant cells can\nassess the hallmarks of genomic instability. That combination is intended to\nhelp distinguish patients whose residual cells appear biologically at lesser\nrisk from patients whose residual disease demonstrate features associated with\na higher risk of relapse or lack of response to therapy.\n\nThe analytic sensitivity of other MRD tests for multiple myeloma are reliant\non the collection of bone marrow, a significantly invasive procedure, using\nnext-generation flow cytometry (including EuroFlow next-generation flow, or\n\"NGF\") or next-generation sequencing such as Adaptive Biotechnologies'\nclonoSEQ® assay. Those methods quantify residual tumor burden. Because of the\nrequirement for bone marrow aspirates for a disease that is typically patchy\nin its distribution, there is a risk of false negative results. In the case of\nclonotype-dependent NGS, there is the added requirement that a dominant clone\ncan first be identified. Importantly, both of these tests provide limited\ninformation about the biological aggressiveness of any cells that remain.\n\nThe Company previously reported a head-to-head analysis of blood-based\nTELO-MRD against matched bone-marrow EuroFlow NGF. Among 42 evaluable samples\nwith exact patient- and date-matched EuroFlow NGF results, TELO-MRD detected\ncirculating myeloma cells in 39/42 samples (92.9%), compared with MRD\ndetection in 23/42 samples (54.8%) by EuroFlow NGF. That comparison was based\non a limited, matched cohort and requires confirmation in larger, independent\nstudies.\n\nThe Company is now reporting a separate comparison of blood-based manual TELO\nenumeration with matched bone-marrow Adaptive clonoSEQ MRD results from two\nindependent research cohorts at Cleveland Clinic and Jewish General Hospital.\nA total of 17 matched comparisons were available, including baseline clonality\nassessments and longitudinal MRD follow-up samples. Manual TELO blood\nenumeration identified circulating plasma cells in every evaluable specimen,\nincluding all cases that were Adaptive-positive or Positive Below Limit of\nDetection.\n\nAmong 10 matched longitudinal MRD assessments, all Adaptive-positive samples\nand all Positive-Below-LOD samples (5 of 10) were also positive by TELO. In\naddition, all 4 samples classified as MRD-negative by Adaptive retained\ndetectable circulating plasma cells by TELO enumeration, and the 1 sample that\nwas not evaluable by Adaptive was TELO-positive. No case was identified in\nwhich Adaptive detected residual disease while TELO blood enumeration was\nnegative. These blood and bone-marrow results are complementary comparisons of\ndifferent sample types and methods, not a claim that the assays are\ninterchangeable.\n\nTwo patients were not trackable by Adaptive because a dominant clonotype could\nnot be established. TELO identified circulating plasma cells in these\npatients, indicating that cell-based analysis remained informative when\nclonotype-dependent molecular MRD could not be performed. The Adaptive\ncomparison is based on a limited research dataset, includes manual\nenumeration, and requires confirmation in larger, independent studies with\nstandardized assay procedures.\n\n\"These additional research results are consistent with what we have seen\nversus bone-marrow flow cytometry,\" said John Farlinger, Chief Executive\nOfficer and Chairman of Telo Genomics. \"In this Adaptive clonoSEQ comparison,\nblood-based TELO enumeration was positive in every Adaptive-positive sample\nreviewed and also detected circulating plasma cells in Adaptive-negative and\nnon-evaluable samples. We believe a blood-based, cell-based method can\ncomplement marrow NGS and NGF, particularly when a clone cannot be tracked or\nresidual cells may be missed in a single marrow site.\"\n\n\"Direct identification of circulating myeloma cells does not depend on first\nlocking a dominant clonotype,\" said Dr. Sabine Mai, Co-Founder and Director of\nTelo Genomics. \"That is a practical difference versus clonotype-dependent NGS.\nThese data are preliminary, the sample size is small, and blood is not the\nsame compartment as bone marrow. The next step is to confirm both detection\nand the biological profiling of those cells in larger studies.\"\n\n\"Accurate, reliable and efficient peripheral blood MRD testing is a priority\nfor our patients with myeloma who are currently undergoing recurrent bone\nmarrow biopsies for this important disease response assessment. Telo not only\nachieves this need, but with the single cell telomere technology can go well\nbeyond MRD assessment to help us better understand the behavior of plasma\ncells. I am quite excited about future research results as we continue to work\nwith Telo,\" said Dr. Sandra Mazzoni, of the Cleveland Clinic.\n\nThe study was a limited, matched research comparison. TELO counts in this\ndataset were generated by manual enumeration. Differences between a blood\nassay and a bone-marrow NGS assay may reflect residual cells in circulation,\nspatial heterogeneity of myeloma, differences in analytical targets, or\nfalse-positive or false-negative calls by either method. These results should\nnot be interpreted as a head-to-head clinical performance claim or as a basis\nfor treatment decisions.\n\nWhile TELO-MRD is not yet commercially available, the Company intends to\ncontinue development of TELO-MRD, including analytical validation of automated\nworkflows, with the objective of a commercial application by the end of\ncalendar 2027.\n\nMultiple myeloma remains incurable. Therapy has extended survival, but\nresidual cancer cells persist and most patients eventually relapse. The\nCompany believes that combining sensitive blood-based detection of residual\nmyeloma cells with single-cell 3D telomere profiling could, if further\nvalidated, add information beyond tumor-burden measurements from bone-marrow\nNGF or NGS alone.\n\nAbout Telo Genomics\n\nTelo Genomics is a biotech company pioneering the most comprehensive telomere\nplatform in the industry with powerful applications and prognostic solutions.\nThese include liquid biopsies and related technologies in oncology and\nneurological diseases. Liquid biopsy is a rapidly growing field of significant\ninterest to the medical community for being less invasive and more easily\nreplicated than traditional diagnostic approaches. By combining our team's\nconsiderable expertise in quantitative analysis of 3D telomeres with molecular\nbiology and artificial intelligence to recognize disease associated genetic\ninstability, Telo Genomics is developing simple and accurate products that\nimprove day-to-day care for patients by serving the needs of pathologists,\nclinicians, academic researchers and drug developers. The benefits of our\nproprietary technology have been substantiated in 190+ peer reviewed\npublications and in 30+ clinical studies involving more than 3,000 patients\nwith multiple cancers and Alzheimer's disease. Our lead application, Telo-MM,\nis being developed to provide important, actionable information to medical\nprofessionals in the treatment of multiple myeloma, a deadly form of blood\ncancer. For more information, please visit www.telodx.com.\n\nFor further information, please contact:\n\nJohn Price, Chief Financial Officer\nJohn.Price@telodx.com\nTel: 408-550-5767\n555 Richmond Street West\nToronto, ON, Canada, M5V 3B1\nwww.telodx.com\n\nNeither the TSX Venture Exchange nor its Regulation Services Provider (as such\nterm is defined in the policies of the TSX Venture Exchange) accepts\nresponsibility for the adequacy or accuracy of this release.\n\nCautionary Note Regarding Forward-Looking Statements\n\nCertain information in this news release may constitute \"forward-looking\ninformation\" under Canadian securities legislation. Forward-looking\ninformation is often identified by words such as \"intends,\" \"believes,\" \"may,\"\n\"could,\" \"objective,\" \"estimate,\" or statements that certain events \"will\"\noccur. Forward-looking statements in this release include, without limitation,\nstatements regarding further development and potential commercialization of\nTELO-MRD by the end of calendar 2027; the complementary role of TELO-MRD\nrelative to bone-marrow NGF and NGS assays; potential future applications of\nthe platform; and the Company's plans to continue research, analytical\nvalidation and development. Forward-looking statements are based on\nassumptions that the Company considers reasonable as of the date of this\nrelease, including that additional studies will confirm the results described\nherein, that development and regulatory or laboratory-developed-test pathways\nwill proceed as planned, and that funding and collaboration partners will\nremain available. Those assumptions may prove incorrect. Actual results may\ndiffer materially because of known and unknown risks and uncertainties,\nincluding the risk that additional clinical data will not confirm these\nfindings, that comparisons of blood-based and bone-marrow assays will be\ninterpreted differently by clinicians or regulators, that apparent\nTELO-positive / NGS-negative results will not be reproduced or will not prove\nclinically meaningful, that commercialization may be delayed or may not occur,\nand other risks described in the Company's filings on SEDAR+. Readers should\nnot place undue reliance on forward-looking statements. The Company does not\nundertake to update forward-looking statements except as required by\napplicable securities laws.\n\n\nTo view the source version of this press release, please visit\nhttps://www.newsfilecorp.com/release/316474"},"type":"article","timestamp":"2026-09-29T07:30:16.133974117Z","server_sent_at_ms":1790667016133},"received_at":"2026-09-29T07:30:16.185Z","source_url":"https://www.newsfilecorp.com/release/316474"},"analysis":{"id":"143591","press_release_id":"154837","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["Very small research cohorts (17 matched clonoSEQ comparisons, 42 EuroFlow samples) with manual enumeration","Company explicitly states results are not a head-to-head clinical performance claim and not a basis for treatment decisions","TELO-MRD is not yet commercially available; commercialization targeted only by end of 2027"],"eventType":"clinical_trial","narrative":"Telo Genomics reported additional clinical research results showing blood-based TELO-MRD detected circulating plasma cells in every evaluable matched sample versus bone-marrow Adaptive clonoSEQ testing across Cleveland Clinic and Jewish General Hospital cohorts.\n\nIn the previously reported EuroFlow NGF comparison, TELO-MRD detected myeloma cells in 39/42 matched samples (92.9%) versus 23/42 (54.8%) for bone-marrow flow cytometry, though the company cautions these are limited, preliminary datasets requiring confirmation in larger independent studies.\n\nTELO-MRD remains non-commercial, with analytical validation of automated workflows underway targeting a commercial application by the end of calendar 2027.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Early liquid-biopsy MRD data beats bone-marrow benchmarks, but tiny preliminary cohorts and 2027 commercialization keep this speculative."},"keyFigures":{"drugName":"TELO-MRD","phaseOfTrial":"clinical research (matched comparison cohorts)","customDimensions":{"commercial_target":"commercial application by end of calendar 2027","euroflow_detection_rate":"54.8% (23/42)","euroflow_matched_samples":42,"clonoseq_matched_comparisons":17,"longitudinal_mrd_assessments":10,"telo_detection_rate_euroflow_comparison":"92.9% (39/42)"}},"quotedText":"blood-based TELO enumeration was positive in every Adaptive-positive sample reviewed and also detected circulating plasma cells in Adaptive-negative and non-evaluable samples","namedEntities":{"people":[{"name":"John Farlinger","role":"CEO and Chairman"},{"name":"Dr. Sabine Mai","role":"Co-Founder and Director"},{"name":"Dr. Sandra Mazzoni","role":"Cleveland Clinic investigator"},{"name":"John Price","role":"CFO"}],"products":["TELO-MRD","TeloView","clonoSEQ","Telo-MM"],"companies":[{"name":"Telo Genomics Corp.","ticker":"TELO","relationship":"filer"},{"name":"Adaptive Biotechnologies","relationship":"competitor"},{"name":"Cleveland Clinic","relationship":"research partner"},{"name":"Jewish General Hospital","relationship":"research partner"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"Positive early research data for TELO-MRD versus clonoSEQ and EuroFlow NGF, but the company explicitly labels the datasets small, preliminary, non-commercial, and not head-to-head performance claims. No revenue or regulatory milestone."},"tickerRelevance":{"others":[],"primary":"TELO"},"globalImportance":12,"audienceRelevance":8,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"early clinical research data","issuerAuthored":true,"commercialStage":"pre-commercial"}},"event_type":"clinical_trial","event_type_secondary":null,"sentiment":"bullish","material_impact_score":2,"narrative":"Telo Genomics reported additional clinical research results showing blood-based TELO-MRD detected circulating plasma cells in every evaluable matched sample versus bone-marrow Adaptive clonoSEQ testing across Cleveland Clinic and Jewish General Hospital cohorts.\n\nIn the previously reported EuroFlow NGF comparison, TELO-MRD detected myeloma cells in 39/42 matched samples (92.9%) versus 23/42 (54.8%) for bone-marrow flow cytometry, though the company cautions these are limited, preliminary datasets requiring confirmation in larger independent studies.\n\nTELO-MRD remains non-commercial, with analytical validation of automated workflows underway targeting a commercial application by the end of calendar 2027.","key_figures":{"drugName":"TELO-MRD","phaseOfTrial":"clinical research (matched comparison cohorts)","customDimensions":{"commercial_target":"commercial application by end of calendar 2027","euroflow_detection_rate":"54.8% (23/42)","euroflow_matched_samples":42,"clonoseq_matched_comparisons":17,"longitudinal_mrd_assessments":10,"telo_detection_rate_euroflow_comparison":"92.9% (39/42)"}},"named_entities":{"people":[{"name":"John Farlinger","role":"CEO and Chairman"},{"name":"Dr. Sabine Mai","role":"Co-Founder and Director"},{"name":"Dr. Sandra Mazzoni","role":"Cleveland Clinic investigator"},{"name":"John Price","role":"CFO"}],"products":["TELO-MRD","TeloView","clonoSEQ","Telo-MM"],"companies":[{"name":"Telo Genomics Corp.","ticker":"TELO","relationship":"filer"},{"name":"Adaptive Biotechnologies","relationship":"competitor"},{"name":"Cleveland Clinic","relationship":"research partner"},{"name":"Jewish General Hospital","relationship":"research partner"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-29T07:30:23.716Z","global_importance":12,"audience_relevance":8,"importance_components":{"tickerTier":"micro-cap","eventGravity":"early clinical research data","issuerAuthored":true,"commercialStage":"pre-commercial"}},"durationMs":6874,"modelName":"glm-5.3-flashx"}}